167 related articles for article (PubMed ID: 8874217)
1. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
Widmer L; Pichert G; Jost LM; Stahel RA
Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
[TBL] [Abstract][Full Text] [Related]
2. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
Léonard BM; Hétu F; Busque L; Gyger M; Bélanger R; Perreault C; Roy DC
Blood; 1998 Jan; 91(1):331-9. PubMed ID: 9414302
[TBL] [Abstract][Full Text] [Related]
3. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma.
Voso MT; Hohaus S; Moos M; Haas R
Blood; 1997 May; 89(10):3763-8. PubMed ID: 9160682
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expansion of CD34-positive peripheral blood progenitor cells from patients with non-Hodgkin's lymphoma: no evidence of concomitant expansion of contaminating bcl2/JH-positive lymphoma cells.
Yao M; Fouillard L; Lemoine FM; Bouchet S; Firat H; Andreu G; Gorin NC; Douay L; Lopez M
Bone Marrow Transplant; 2000 Sep; 26(5):497-503. PubMed ID: 11019838
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells.
Vogel W; Behringer D; Scheding S; Kanz L; Brugger W
Blood; 1996 Oct; 88(7):2707-13. PubMed ID: 8839866
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
9. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
10. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Karcher A; Möhle R; Witt B; Goldschmidt H; Frühauf S; Flentje M; Wannenmacher M; Hunstein W
J Clin Oncol; 1994 Aug; 12(8):1685-92. PubMed ID: 7518860
[TBL] [Abstract][Full Text] [Related]
11. Positive selection of CD34+ cells from cryopreserved peripheral blood stem cells after thawing: technical aspects and clinical use.
Bohbot A; Lioure B; Faradji A; Schmitt M; Cuillerot JM; Laplace A; Oberling F
Bone Marrow Transplant; 1996 Feb; 17(2):259-64. PubMed ID: 8640176
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
[TBL] [Abstract][Full Text] [Related]
13. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of hematopoietic progenitors from CD34+ cells selected from leukapheresis products of lymphoma and myeloma patients: feasibility and enhancement by fibronectin.
Mahé B; Pineau D; Robillard N; Accard F; Hermouet S
J Hematother; 1996 Dec; 5(6):671-9. PubMed ID: 9117256
[TBL] [Abstract][Full Text] [Related]
16. Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system.
Di Nicola M; Siena S; Corradini P; Bregni M; Milanesi M; Magni M; Ruffini PA; Ravagnani F; Tarella C; Gianni AM
Bone Marrow Transplant; 1996 Dec; 18(6):1117-21. PubMed ID: 8971381
[TBL] [Abstract][Full Text] [Related]
17. Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells.
Yerly-Motta V; Racadot E; Fest T; Bastard C; Ferrand C; Deschaseaux ML; Herve P
Leuk Lymphoma; 1996 Oct; 23(3-4):313-21. PubMed ID: 9031112
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
[TBL] [Abstract][Full Text] [Related]
19. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
Davis TA; Maloney DG; Czerwinski DK; Liles TM; Levy R
Blood; 1998 Aug; 92(4):1184-90. PubMed ID: 9694706
[TBL] [Abstract][Full Text] [Related]
20. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD).
Olsson K; Gerard CJ; Zehnder J; Jones C; Ramanathan R; Reading C; Hanania EG
Leukemia; 1999 Nov; 13(11):1833-42. PubMed ID: 10557059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
